A doctor friend in Australia has Emailed us with some information presented at ASH by an Australian pharmaceutical company called ChemGenex.
Their drug, Omacetaxine, has been trialled on 21 CML patients who have become resistant to Glivec through the “T315I mutation”.
They say that results from tests on 21 patients in various stages of the disease showed that 91 per cent of them had responded to the ChemGenex treatment. It seems this drug works in a different way to Glivec.
The link to the ChemGenex press release is ChemGenex News
Hopefully, this is more good news on the drug treatment front.
David